IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
424B5 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
424B5 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
10-K/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
SCHEDULE 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)
8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
3 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) (the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6 million, before deducting underwriting discounts and commissions and offering expenses. Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering. All of the shares of common stock to be sold in the offering will be sold by the Company. In ad
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) (the "Company") a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering. The offering is being made pursuant to
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its preliminary unaudited selected financial results for the fiscal second quarter and six months ended December 31, 2024. For the fiscal 2
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening Most recent client added to INBS's portfolio of more than 400 accounts across the globe, as the Company plans entry into the US market in 2025 NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Quantum Traffic Management ("Quantum TM"), a leading UK-based traffic management provider, has adopted INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites t
NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Princebuild, a leading construction firm with seven sites and operations spanning six key divisions, has adopted INBS' Intelligent Fingerprinting Drug Screening System. Princebuild has made a strategic decision to move from saliva testing to fingerprint drug screening in order to implement a more streamlined, in-house solution that prioritizes efficiency, accuracy, and respect for employee privacy. Princebuild, an established construction company in Peterborough,
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System (the "System"), an innovative, rapid and pain-free method for drug screening. The submission represents a critical milestone on the Company's path to realizing its goal of entering the US market with its drug testing solution in 2025. The Company's 510(k) submission included per
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024. During the event, management will discuss the Company's recent clinical study results, path to FDA 510(k) submission, and offer investors an opportunity to ask questions. Virtual Fireside Chat Details:Dates: December 11, 2024Presentation Time: 4:30 p.m. ETRegistration Link: https://us02web.zoom.us/webinar/register/WN_FtL7WYRoRa2q
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its method comparison study (the "Method Study") on its Intelligent Fingerprinting Drug Screening System (the "System"). The Method Study confirmed the sensitivity, specificity, accuracy, and usability
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets' 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL. Noble Capital Markets' 20th Annual Emerging Growth Equity ConferenceDates: December 3-4, 2024Location: Florida Atlantic University, Boca Raton, FLPresentation Day and Time: Wednesday, December 4, 2024, at 2:00 p.m. ET Presentation Location: Presentation Room 3 A link to the recording of the presentation
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six
- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million,
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions,
- Combined full-year revenue and government support income increased 355% year-over-year - - Received guidance from U.S. FDA on a regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge - - Granted 13th patent following award of U.K. patent relating to DSR-Plus Cartridge Reader - - Recently secured 8 new customers just two months into product launch in Australia - NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal fourth quarter
- Combined revenue and government support income increased 199% year-over-year - - Sequential revenue growth of 28% -- Filed 513(g) submission with U.S. FDA for Intelligent Fingerprinting Drug Screening Cartridge - - Granted U.K. patent relating to DSR-Plus Cartridge Reader - - Completion of Milestone 7, key phase of biosensor platform development - NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a bu
- Second quarter total revenue and government support income increased over 100% year-over-year - - Government support income increased 52% for the quarter ended December 31, 2022 compared to the prior corresponding period, mainly due to qualifying expenditures for completion of Milestone 7 - - Successful completion of Milestone 7, a key phase of its biosensor platform development - - Cash and cash equivalents at quarter-end totaled $2.9 million - NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (NASDAQ:INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions,